KPIs & Operating Metrics(New)
Growth Metrics

Teva Pharmaceutical Industries (TEVA) EPS (Basic) (2016 - 2026)

Teva Pharmaceutical Industries filings provide 18 years of EPS (Basic) readings, the most recent being $0.32 for Q1 2026.

  • On a quarterly basis, EPS (Basic) rose 68.42% to $0.32 in Q1 2026 year-over-year; TTM through Mar 2026 was $1.37, a 220.18% increase, with the full-year FY2025 number at $1.23, up 184.83% from a year prior.
  • EPS (Basic) hit $0.32 in Q1 2026 for Teva Pharmaceutical Industries, down from $0.42 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $0.42 in Q4 2025 to a low of -$1.17 in Q4 2022.
  • Median EPS (Basic) over the past 5 years was -$0.12 (2024), compared with a mean of -$0.15.
  • Biggest five-year swings in EPS (Basic): crashed 1328.57% in 2022 and later soared 321.05% in 2025.
  • Teva Pharmaceutical Industries' EPS (Basic) stood at -$1.17 in 2022, then soared by 135.04% to $0.41 in 2023, then plummeted by 146.34% to -$0.19 in 2024, then soared by 321.05% to $0.42 in 2025, then fell by 23.81% to $0.32 in 2026.
  • The last three reported values for EPS (Basic) were $0.32 (Q1 2026), $0.42 (Q4 2025), and $0.38 (Q3 2025) per Business Quant data.